Obstructive sleep apnoea does not cause elevated plasma levels of N-terminal pro-brain natriuretic peptide Source: Eur Respir J 2005; 26: Suppl. 49, 38s Year: 2005
Brain natriuretic peptide levels in the obstructive sleep apnoea/hypopnoea syndrome Source: Eur Respir J 2005; 26: Suppl. 49, 355s Year: 2005
Natriuretic peptide in sleep apnea – relation with hypoxia Source: Eur Respir J 2007; 30: Suppl. 51, 334s Year: 2007
Vasopressin, atrial natriuretic peptide and adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnoea syndrome Source: Annual Congress 2013 –Heart, blood and metabolism in sleep disordered breathing Year: 2013
Cardiovascular diseases are responsible for increased plasma NT-proBNP level in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA Year: 2012
Relationship between NT-proBNP plasma level and nocturia in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2007 - Systemic effects of obstructive sleep apnoea Year: 2007
NT-pro BNP is a marker for cardiovascular dysfunction due to obstructive sleep apnea syndrome Source: Annual Congress 2010 - Nocturnal cardiology: chronic heart failure, acute chest syndrome, coronary artery disease and collagen vascular disease Year: 2010
Relationship between plasma NT-proBNP level and cardiovascular complications in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2010 - Nocturnal cardiology: chronic heart failure, acute chest syndrome, coronary artery disease and collagen vascular disease Year: 2010
Influence of body weight on plasma NT-proBNP in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2007 - Cardiovascular and respiratory control in obstructive sleep apnoea Year: 2007
Plasma orexin-A levels in patients with obstructive sleep apnea syndrome Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Circadian rhythm of CRP, Pro-BNP, leptin and cortisol in obstructive sleep apnea and COPD desaturors: Preliminary data Source: Annual Congress 2010 - Biomarkers for oxidative stress, inflammation and cardiovascular function in sleep apnoea Year: 2010
The incidence and significance of elevated B-type natriuretic peptide levels in patients hospitalized with apparent respiratory diseases Source: Eur Respir J 2004; 24: Suppl. 48, 279s Year: 2004
Brain natriuretic peptide (BNP) determination in patients hospitalized for COPD exacerbation Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008
BNP or VEGF levels do not predict disease severity in obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2005; 26: Suppl. 49, 40s Year: 2005
Determination of B-type natriuretic peptide in patients with chronic heart failure and Cheyne-Stokes respiration Source: Eur Respir J 2004; 24: Suppl. 48, 563s Year: 2004
Presence of inspiratory crackles (IC) in stable chronic obstructive pulmonary disease (COPD) patients; correlation with plasma N-terminal pro-brain natriuretic peptide (NT-BNP) levels Source: Annual Congress 2008 - Assessment of the respiratory system Year: 2008
Serum leptin levels in obstructive sleep apnoea patients Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Reduced plasma fetuin-A levels in patients with obstructive sleep apnoea}, Source: Eur Respir J 2012; 40: 1046-1048 Year: 2012
NT-proBNP in obstructive sleep apnoea (OSA) Source: Eur Respir J 2006; 28: Suppl. 50, 415s Year: 2006
Relationship between NT-proBNP level, echocardiographic parameters and cardiovascular diseases in patients with obstructive sleep apnoea (OSA) Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA Year: 2012